

# Annex B - Summary of Studies

## In this guide

### [In this guide](#)

1. [Introduction - Second Draft Statement on the Safety of Ginger Supplement use in Pregnancy](#)
2. [Annex A - Second Draft Statement on the Safety of Ginger Supplement Use in Pregnancy](#)
3. [Annex A - Information on ginger](#)
4. [Annex A - Exposure](#)
5. [Annex A - Conclusions of the Committee](#)
6. [Annex A - References](#)
7. [Annex B - Summary of Studies](#)
8. [Annex C - Assessment of Exposure](#)

## Human Studies

<b>Author/Date</b>	<b>Study type</b>	<b>Study size/No. of Patients at End</b>	<b>Exposure (ginger dose/day)</b>	<b>Study period</b>	<b>Length of Treatment (days)</b>	<b>Main outcome measures</b>	<b>Main results</b>
--------------------	-------------------	--	-----------------------------------	---------------------	-----------------------------------	------------------------------	---------------------

Chittumma <i>et al.</i> , 2007	Randomized double-blind controlled trial.	126/123	Ginger powder capsules (325 mg x2, 3x/d, = 1950 mg/day)	4 days	4	Change in nausea and vomiting scores (3 symptoms on Rhodes index); occurrence of side-effects	Results showed ginger significantly more effective relieving than vit B6 (p <
Ensiyeh <i>et al.</i> , 2005	Double-blind randomised controlled trial.	70/69	Ginger powder capsules (500 mg 2x/d =1000 mg/day)	3 months	4	Severity of nausea (VAS 0-10); number of vomiting episodes; general response to treatment (5-item Likert scale); occurrence of side-effects or adverse pregnancy outcome	two spontaneous abortions ginger 1 in B6 no congenital anomalies observed babies to term

Fischer-Rasmussen <i>et al.</i> , 1991	Double-blind randomised crossover trial	30/27	Ginger powder capsules (250 mg 4 times per day = 1000 mg/day)	11 days	4	Preference of treatment period; relief scores (4-point scoring system); outcome of pregnancy	One spontaneous abortion elected; adverse effects observed; remain subjects
--	---	-------	---	---------	---	--	---

Portnoi, 2003	Not specified	187 pregnant women	Various, not specified	up to 12 months post birth	Minimum of 3 days	Safety and effectiveness of ginger for nausea and vomiting of pregnancy (NVP).	<p>Three malformations were reported in the control group, ventricular septal defect (VSD), lung abnormality, and kidney abnormality (pelvic).</p> <p>One incident of idiopathic central precocious puberty at age 2 years. No significant differences between the two groups in terms of births, spontaneous abortions, stillbirths, therapeutic abortions, birth weight, or gestational age.</p>
---------------	---------------	--------------------	------------------------	----------------------------	-------------------	--	--

Smith, 2004	Randomized, controlled equivalence trial	291 women, less than 16 weeks pregnant	1.05 g ginger	3 weeks	3 weeks	Ginger versus B6 for the treatment of nausea or vomiting in pregnancy	Three spontaneous abortions in ginger group; 9 abortions in B6 group
Vutyavanich, 2001	Double blind	32	Ginger powder capsules (250 mg 4x/day =1000 mg/day)	5 months	4	Severity of nausea (VAS 0-10); number of vomiting episodes; general response to treatment after 1 week (5-item Likert scale); occurrence of side-effects and adverse pregnancy outcomes	Ginger significantly more effective than the placebo in relieving severity of nausea in pregnancy = 0.014

Willetts <i>et al.</i> , 2003	Double-blind randomised placebo-controlled trial	120/99	Ginger extract capsules (125 mg 4x/d =1000 mg/day)	8 months <sup>4</sup>	Used RINVR to measure frequency, duration, distress caused by nausea, vomiting and retching; long term follow-up for birth outcome	Three spontaneous abortions observed; ginger
-------------------------------	--	--------	--	-----------------------	--	--

## Human studies - Platelet Aggregation

Author/date	Study design	Population/study size	Study Duration	Exposure	Outcome
Bordia <i>et al.</i> , 1997	Placebo controlled trial	Patients with confirmed myocardial infarction N = 60	3 months. Outcomes measured at: baseline, 1.5 months and 3 months.	Dose: 4g per day Unstandardised capsules	Platelet aggregation- Agonist(s): A Epi;
Bordia <i>et al.</i> , 1997	No data.	No data.	No data.	No data.	Fibrinogen;
Bordia <i>et al.</i> , 1997	No data.	No data.	No data.	No data.	Fibrinolytic a

Bordia <i>et al.</i> , 1997	No data.	20	1 day. Outcomes measured at: baseline, 4 hours post-consumption	10 g single dose. Unstandardised capsules	Platelet aggregation - Agonist(s): ADP, Epi
Jiang <i>et al.</i> , 2004	Randomized, open label, three-way crossover trial	Healthy male volunteers Age: 20-36 N =12	Total study period: 3x13 days, 14 days washout period between each study period.	Dose: 3.6g (3x 0.4g, 3x per day) Unstandardized capsules Consumed with 25 mg dose of rac-warfarin, consumed once per study period.	Platelet aggregation Agonist: AA; Plasma warfarin enantiomer p binding & warfarin enantiomer concentration Urinary S-7-hydroxywarfarin
Lumb. 1994	Randomised, double-blinded placebo-controlled crossover trial	Healthy male volunteers N=8	Total study period: 2 x 1 day, at least 14 days washout period. Outcomes measured immediately before, 3 hrs, and 24 hrs post consumption of ginger	Dose: 2g (4 x 500 mg) dried ginger per day Unstandardized capsules	Platelet aggregation - Agonist(s): ADP, collagen, ristocetin; Bleeding time; Platelet count; Thromboelastography

Rubin <i>et al.</i> , 2019	Case report	Female, 70 yrs	No data.	48 mg daily Chewable ginger supplement for approx. 1 month	INR - 8.0 approx month after t ginger supple
-------------------------------	-------------	----------------	----------	---	--

Srivastava 1989	Open-label single-arm trial	Healthy female volunteers, N = 7	Total study period: 7 days. Outcomes measured at baseline and 7 days post- consumption	Dose: 5g raw ginger per day	Platelet throm B2 productio
--------------------	-----------------------------------	-------------------------------------	--	-----------------------------------	--------------------------------



Verma <i>et al.</i> , 1993	Randomised placebo controlled trial	Healthy male volunteers; N = 20	Total study period: 14 days, high calorie diet for first 7 days, high- calorie diet and ginger/placebo consumed for next 7 days. Outcomes measured at baseline, 7, and 14 days	Dose: 5g (4 x 625 mg, twice per day); dry ginger powder - Unstandardized capsules Consumed with 100g (2x50g) butter, 2 cups of milk, 8 slices of bread.	Platelet aggr Agonist(s): A Epi
-------------------------------	--	---------------------------------------	---	--	---------------------------------------

Young <i>et al.</i> , 2006	Not specified	20	72 days	1 g ginger (+ 10 mg nifedipine)	Synergistic e ginger and n on anti-plate aggregation normal huma volunteers an hypertensive patients.
-------------------------------	------------------	----	---------	---------------------------------------	--

### ***In vitro* studies**

<b>Author</b>	<b>Test System</b>	<b>Exposure</b>	<b>Characterisation of test substance</b>	<b>Main outcome measure</b>	<b>Outco</b>
---------------	--------------------	-----------------	---	-------------------------------------	--------------



No data.

No data.

No data.

No data.

No data.

Char  
cellu  
and p  
cont  
dose  
man  
conc  
μM)

No data.

No data.

No data.

No data.

No data.

Signi  
decre  
cardi  
differ  
for a  
conc  
exce  
in ES

No data.

No data.

No data.

No data.

No data.

Signi  
decre  
cellu  
and p  
cont  
cell-c  
cardi  
with  
6-gin  
conc  
expo

Nakamura &  
Yamamoto  
(1982)

Escherichia coli  
Hs30

Not  
specified

Juice of ginger  
rhizome, 6-  
gingerol

Mutagenicity

ginge  
supre  
spon  
muta  
ginge  
muta  
isola

Nakamura & Yamamoto 1983	Escherichia coli Hs30	Not specified	6-shogaol, 6-gingerol	Mutagenicity	[6]-S 104 t muta conc 700u [6]-g
Nirmala <i>et al.</i> , 2007	Wistar rats, male	Salmonella typhimurium strains TA 98 and TA 100	Ginger paste and powder, unboiled, boiled, unfried, fried Ames test: Ginger paste: 1, 2 and 3 mg; powder: 0.5, 1 and 1.5 g	Anti-mutagenicity	Anti-poten unalt treat ginge
Plengsuriyakarn <i>et al.</i> , 2012	Cholangiocarcinoma (CCA) cell line 6 (CL-6), hepatocarcinoma (HepG2) and normal human renal epithelium (HRE)	1.95, 3.90, 7.81, 15.62, 31.25, 62.5, 125, and 250 µg/ml	Crude ethanolic ginger extract	Cytotoxicity	IC50 cytot 10.9 53.1
Sivaswami <i>et al.</i> , 1991 (Abstract)	Salmonella typhimurium strains TA 98, TA 100 and TA 1535	Unknown	Essential oil from ginger	Mutagenicity	Non
Soudamini <i>et al.</i> , 1995	Salmonella typhimurium strains TA 100, 98 and TA 1535	25 and 50 mg/plate	ethanolic mixture of powdered ginger	Mutagenicity	muta both and both conc

Zaeoung <i>et al.</i> , 2005	breast (MCF7) and colon (LS174T) cell lines	Not specified	aqueous extract and volatile oils	Cytotoxicity	IC50 µg/m
---------------------------------	---	------------------	--------------------------------------	--------------	--------------

### ***In vivo studies***

<b>Author</b>	<b>Test System</b>	<b>Study size</b>	<b>Exposure</b>	<b>Characterisation of test substance</b>	<b>Duration</b>
Alnaqeeb <i>et al.</i> , 2003 (abstract)	Rats, female	Unknown	Oral and intraperitoneal. 50 mg/kg and 500 mg/kg	Aqueous ginger extract	28 days
Dissabandara & Chandrasekara, 2007	Sprague-Dawley rats	15 in 3 groups, otherwise not specified	Oral: 500 mg/kg/day and 1000 mg/kg/day during days 5 to 15 of gestation	Powdered ginger extract	Animals treated with ginger for 10 days

ElMazoudy and Attia, 2018 (abstract only)	ICR mice	Unknown	250, 500, 1000, or 2000 mg/kg bw/d aqueous ginger extract.	Powdered dried ginger root	35-day treatment study; 20 day study (antifertility and abortifacien loss)
Hosseini <i>et al.</i> , 2015 (abstract only)	Rats, female and male offspring	72 (groups of 9)	Oral: 50, 100 and 200 mg/kg bw during neonatal and perinatal periods	Alcoholic ginger extract	Unknown

Jeena *et al.*,  
2011

Wistar rat

30

Oral: 100, 250,  
and 500 mg/kg Ginger essential  
per day once oil  
daily

13 weeks

Malik and Sharma, 2011	Wistar rat, male	Not specified	gastric gavage: 250, 500 and 1000 mg/kg, (corresponding to 5, 10 and 20% of the NOAEL of the lyophilised ginger powder (5000 mg/kg)	Lyophilised ginger juice powder	Experiment 2: 8 weeks. Exp 1&2 not specified
Plengsuriyakarn <i>et al.</i> , 2012	OV and nitrosamine (OV/DMN)-induced CCA hamsters	90	1000, 3000, and 5000 mg/kg bw/d	No data.	30 days
Rong <i>et al.</i> , 2009	Sprague-Dawley rats, male and Female	40	Gavage: 500, 1000 and 2000 mg/kg bw/day	Powdered Japanese ginger,	37



Shalaby and  
Hamowieh,  
2010

Sprague Dawley rats,  
120

Oral, 5 to 17.5  
g/kg bw

water or  
methanolic ginger extract  
65 days

No data.

No data.

No data. No data.

No data.

No data.

No data.	No data.	No data.	100 and 200 mg/kg bw for 65 consecutive days and water extracts at doses of 150 and 300 mg/kg bw	No data.	No data.
----------	----------	----------	--	----------	----------

Weidner & Sigwart, 2001	Wistar rats, pregnant female	176 (88 Females)	Gastric intubation: 100, 333 and 1000 mg/kg from days 6-15	EV.EXT 33, a patented Zingiber officinale extract (comprising 6-gingerol, 8-gingerol, 10-gingerol, 6-shogaol, and 8-shogaol (1.9 w/w of the extract))	21 days
-------------------------	------------------------------	------------------	--	---	---------

Wilkinson 2000	Sprague-Dawley rats, F	43	Oral, drinking water on days 6-15	20 g/L or 50 g/L ginger tea	20 days
----------------	------------------------	----	-----------------------------------	-----------------------------	---------

### Effect on CYPs and prostaglandin activity

Author	Test System	Exposure	Characterisation of test substance	Main outcome measure	Outcome
Dugasani <i>et al.</i> , 2010	Mouse leukaemic monocyte (RAW 264.7) macrophages and human polymorphonuclear neutrophils (PMN)	1, 3 and 6 $\mu$ M	[6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol	Compare the antioxidant and antiinflammatory activities of gingerols and their natural analogues to determine their structure-activity relationship and molecular mechanisms.	Dose dependant inhibition of activated PGE2 release. Inhibition reached 56, 66, 73 and 87%, respectively at 6 $\mu$ M

Jolad et al., 2004	HL-60 cells	Not specified	Ginger constituents: gingerols, shogaols, 3-dihydroshogaols, gingerdiols	Effects of ginger components on LPS-induced PGE2 production	No cytotoxicity demonstrated
Jolad et al., 2005	HL-60 cells	Not specified	Ginger constituents containing gingerols, shogaols, 3-dihydroshogaols, gingerdiols	Effects of ginger components on LPS-induced PGE2 production	Inhibition of LPS-stimulated PGE2 production (IC50 = 0.08 ug/ml with Ginger fractions)
Kim et al., 2012	Human liver microsomes	0.05-5 ug/ml	Aqueous ethanolic ginger extract (30% EtOH)	Inhibitory effect on CYP450-mediated drug metabolism	Concentration dependent inhibitory effects on CYP2C19; IC50 value 3.8 g/ml
Kimura et al., 2010	Human CYP3A4 and CYP2C9 microsomes	Not specified		Inhibitory effect on CYP3A4 and CYP2C9 activity	significant inhibition of CYP3A4 IC50 5.1u g/ml CYP2C9 IC50 (10ug/ml) activity

Lantz et al., 2007	U937 cells	0.1 ug/ml for 6 hrs	Ginger extract and mixtures of 6-, 8- 10-gingerols and 6-, 8-, 10-shogaols	Effect on inflammatory mediator production	No effect on COX-2 expression
--------------------	------------	---------------------	--	--	-------------------------------

Mukkavilli  
*et al.*,  
2014

Human liver  
microsomes

Ginger  
extract: 500  
mg/ml  
(containing  
15 mg/  
ml 6G, 3.4  
mg/ml 8G,  
3.9 mg/ml  
10G, 3.0  
mg/ml 6S);  
All  
individual  
components  
of gingerols  
assessed at  
100 mM  
(equivalent  
to 29 mg/ml  
6G, 32  
mg/ml 8G,  
35 mg/ml  
10G and  
28 mg/ml of  
6S)

Ginger extract:  
(containing 6-  
Gingerol, 8-  
Gingerol, 10-  
Gingerol, 6-  
Shogaol). All  
individual  
components of  
gingerols were  
assessed at 100  
mM  
equivalent to 29  
mg/mL 6G, 32  
mg/mL 8G, 35  
mg/mL 10G and  
28 mg/mL of 6S.

Effect of ginger  
extract and  
major  
constituents on  
CYP P450  
enzyme activity

Inhibition of  
CYP1A2 (IC<sub>50</sub> -  
-  
221.5 mg/  
by ginger  
extract. No  
effect on  
CYP2A6;  
maximum  
inhibition of  
CYP2B6: IC<sub>50</sub> -  
- 22 mg/m  
IC<sub>50</sub> - 122  
mg/mL  
against  
CYP2C8  
in the  
presence of  
amodiaquin  
IC<sub>50</sub> - 93.5  
mg/mL  
against  
CYP2C9,  
in the  
presence of  
diclofenac  
Inhibition of  
CYP3A in t  
presence of  
testosteron  
no effect i  
the presen  
of midazol

## Effect on Platelet Aggregation

Author	Test System	Study size	Exposure	Characterisation of test substance	Main outcome measure	Out
Srivas, 1984	Human platelets and rat aorta	No data.	15-20 ul (concentrations not given)	Ginger extracts in water, n-hexane, chloroform, and ethyl acetate	Effect of ginger extracts on <i>in vitro</i> platelet aggregation	Inhibi arac acid epir ade diph (AD colla indu plat agg
Srivastava, 1986	Platelet rich plasma (no further information given)	No data.	10-20 ul (concentrations not given)	No data.	Effect of ginger and components on platelet aggregation and eicosanoid biosynthesis	Red thro form from exo AA; of A epir ADP colla indu plat agg



Srivastava 1989	Open-label single-arm trial	Healthy female volunteers, N = 7	Total study period: 7 days. Outcomes measured at baseline and 7 days post- consumption	Dose: 5g raw ginger per day	Platelet thromboxane B2 production	Ging cons resu 37% inhib thro B2 proc (p<
Suekawa <i>et al.</i> , 1986 (abstract only)	Rat hind paw and aorta, rabbits	Unknown	Unknown	6-shogaol	Effect of 6- shogaol on arachidonic acid cascade	Inhil carr indu swe hinc rats arac acid indu plat agg in ra Inhil pros 12 ( rele rat a Poss caus COX inhil

Thomson  
*et al.*,  
2002

Sprague-  
Dawley  
rats, Adult,  
F; *ex vivo* 36

50 mg/kg or  
500 mg/kg daily  
by gavage or  
intraperitoneally  
(IP) for 4 weeks

Aqueous ginger  
extract,  
equivalent of 500  
mg/ml

*ex vivo* effect  
of aqueous  
extract of  
ginger on the  
synthesis of  
thromboxane-  
B2,  
prostaglandin-  
E2, and  
cholesterol,  
triglyceride  
levels in the  
serum of  
normal rats

No data.

No data.

No data.

No data.

No data.

No data.

Seru  
redu  
both  
leve  
dose  
sign  
redu  
seru  
both  
and  
non  
sign  
redu  
the  
TXB  
obs  
wh  
was  
IP b  
sign  
diffe  
from  
grou

Sign  
redu  
leve  
chol  
rats  
high  
No s  
char  
trigl  
leve  
eith  
eith  
or IP

## Herb-drug interactions

Author	Test System	Study size	Exposure of test substance	Characterisation of test substance	Duration	Main outcome measure	Outcome
Al-Omari <i>et al.</i> , 2012	Albino rat, M	30: 5 groups of 6; 72: 12 groups of 6;	25, 50 and 100 mg/kg bw by gavage; single dose (50 mg/kg bw)and up to one week	Ginger crude extract	Multiple dose: 2 weeks; single dose: 1 week	Effect on glibenclamide and insulin; hypoglycaemic and antihyperglycemic effects in normoglycemic- and streptozotocin-induced (STZ) diabetic rats	Significant decrease in blood glucose levels; normoglycemic rats showed significant decrease in STZ-induced hyperglycemia in 5 days
Egashira <i>et al.</i> , 2012	Sprague-Dawley rat, M (7 weeks old)	Not specified	10 mL/kg orally	50% ginger juice	1-3 days	interaction between ginger juice and tacrolimus	Significant increase in tacrolimus blood concentration in rats with ginger juice compared to those without oral

Okonta  
*et al.*,  
2008

Rabbits  
(3F, 2M) 5

1 ml/kg,  
orally

Ginger extract

3 days

Effect of ginger on  
the  
pharmacokinetics  
of metronidazole

Sig  
inc  
abs  
pla  
life  
dec  
the  
rat  
anc  
of  
me